We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate.
- Authors
Neumeister, P.; Eibl, M.; Zinke-Cerwenka, W.; Scarpatetti, M.; Sill, H.; Linkesch, W.
- Abstract
Monoclonal antibodies recognizing hematopoietic antigens are increasingly being used to target therapy directly at leukemic cells, with the aim of achieving sustained remission with little systemic toxicity. Administration of anti-CD33 calicheamicin immunoconjugate is commonly regarded as being safe, with only moderate systemic non-hematological side effects. We report on two cases of hepatic veno-occlusive disease in heavily pretreated patients presenting with relapsed acute myeloid leukemia (AML). Since significant liver toxicity prevented further specific therapy in both patients, we recommend that antibody therapy with anti-CD33 immunoconjugate should be applied with caution in patients presenting with risk factors for the development of hepatic veno-occlusive disease.
- Subjects
MYELOID leukemia; IMMUNOGLOBULINS; ANTIBODY-toxin conjugates; BIOCONJUGATES; MONOCLONAL antibodies; BILIARY tract
- Publication
Annals of Hematology, 2001, Vol 80, Issue 2, p119
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s002770000239